Hospital systems nationwide struggle with a critical gap: patients with opioid use disorder frequently arrive for emergency medical care, yet their underlying addiction often goes unaddressed during their stay. This creates a revolving door of costly readmissions and missed opportunities for life-saving intervention at a vulnerable moment when patients are already engaged with healthcare.
The START (Substance Use Treatment and Recovery Team) model demonstrates measurable economic value alongside clinical benefits. This specialized hospital-based addiction consultation service generated favorable cost-effectiveness ratios when analyzed through both health sector and societal lenses over 12 months. The intervention increased medication initiation rates and successful linkage to outpatient addiction treatment compared to standard discretionary care by primary medical teams. The economic modeling incorporated quality-adjusted life years and incremental cost-effectiveness ratios using participant-level data from three major academic medical centers.
This finding addresses a persistent challenge in addiction medicine: proving that specialized interventions justify their upfront costs through downstream savings and improved outcomes. Hospital administrators often resist investing in addiction consultation services despite growing opioid-related admissions. The START model's demonstrated cost-effectiveness provides compelling evidence for scaling hospital-based addiction interventions. However, the analysis spans only 12 months, and longer-term economic benefits may be even more substantial given addiction's chronic nature and tendency toward expensive emergency utilization. The academic medical center setting may also limit generalizability to community hospitals with different resource constraints and patient populations.